Relief Therapeutics Holding SA stock PB Ratio (=1.16) is close to 1-year high of 1.16.
The historical rank and industry rank for Relief Therapeutics Holding's PB Ratio or its related term are showing as below:
XSWX:RLF'
s PB Ratio Range Over the Past 10 Years
Min: 0.1 Med: 0.87 Max: 56.92
Current: 1.16
During the past 13 years, Relief Therapeutics Holding's highest PB Ratio was 56.92. The lowest was 0.10. And the median was 0.87.
XSWX:RLF's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.8
vs XSWX:RLF: 1.16
During the past 12 months, Relief Therapeutics Holding's average Book Value Per Share Growth Rate was -34.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -45.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Relief Therapeutics Holding was 69.60% per year. The lowest was -60.00% per year. And the median was -20.40% per year.
Back to Basics: PB Ratio
Relief Therapeutics Holding (XSWX:RLF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Relief Therapeutics Holding PB Ratio Related Terms
Relief Therapeutics Holding PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Relief Therapeutics Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's PB Ratio distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Relief Therapeutics Holding (XSWX:RLF) has a PB Ratio of 1.16 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Relief Therapeutics Holding and its competitors. This is 33% above median its historical median of 0.87. Over the past decade, Relief Therapeutics Holding's PB Ratio has ranged from 0.10 to 56.92.
Is Relief Therapeutics Holding's PB Ratio too high?
Relief Therapeutics Holding's current PB Ratio of 1.16 is 33% above median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 56.92. The Biotechnology industry median PB Ratio is 2.80. Relief Therapeutics Holding's value of 1.16 is 58.6% below this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's PB Ratio compare to KTTA and OSRH?
Relief Therapeutics Holding's PB Ratio of 1.16 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.80. Relief Therapeutics Holding's value of 1.16 is 58.6% below this benchmark. Historically, Relief Therapeutics Holding's own PB Ratio has ranged from 0.10 to 56.92 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 2.80, Relief Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current PB Ratio of 1.16 is 58.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current PB Ratio is 1.16, which is 33% above median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current PB Ratio of 1.16. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current PB Ratio is 1.16, which is 33% above median its 10-year median of 0.87 and 58.6% below the Biotechnology industry median of 2.80. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current PB Ratio is 1.16 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
PB Ratio: 1.16 (33% above median its 10-year median of 0.87)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 58.6% below the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
